on MAAT PHARMA (isin : FR0012634822)
Crossing Thresholds at MAAT PHARMA
On November 19, 2025, MAAT PHARMA announced that Invus Public Equities, LP, based in Bermuda, had crossed the 5% threshold of MAAT PHARMA's share capital and voting rights. This announcement follows a capital increase to which Invus subscribed.
This increase to 6.24% of the share capital, representing 1,170,833 shares, was formally notified by letter and constitutes a significant change in the shareholding structure of MAAT PHARMA. The acquisition is controlled by Mr. Raymond Debanne through Invus.
This operation is part of a capital increase by MAAT PHARMA, as detailed in a press release dated November 14, 2025.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAAT PHARMA news